The efficacy and safety of tislelizumab plus anlotinib as first-line treatment in advanced pulmonary sarcomatoid carcinoma: a single-arm phase II trial - PubMed
5 hours ago
- #first-line therapy
- #immunotherapy combination
- #pulmonary sarcomatoid carcinoma
- Tislelizumab plus anlotinib showed an objective response rate of 55.17% in advanced pulmonary sarcomatoid carcinoma patients.
- The combination achieved a disease control rate of 96.55%, with median progression-free survival of 9.40 months and overall survival of 14.37 months.
- Treatment-related adverse events were common, with hyperuricemia and maculopapular rash being frequent; grade 3-4 events occurred in 27.59% of patients, but no treatment-related deaths were reported.